import { Helmet } from 'react-helmet-async';
import { Link } from 'react-router-dom';
import Navbar from '@/components/Navbar';
import Footer from '@/components/Footer';
import { BreadcrumbNav } from '@/components/seo/BreadcrumbNav';
import { FAQSection } from '@/components/healthcare-research/FAQSection';

const pageUrl = 'https://www.bionixus.com/gcc-pharmaceutical-market-research';

/**
 * FAQs target the stuck GSC queries ranking positions 40–70:
 * "gcc drug repurposing market", "gcc generic injectables market",
 * "gcc biologics market", "saudi arabia precision medicine market".
 * Each question repeats the exact query phrase to win featured snippets.
 */
const FAQ_ITEMS = [
  {
    question: 'What is the size of the GCC biologics market in 2026?',
    answer:
      'The GCC biologics market is estimated at USD 4.8–5.4 billion in 2026, driven by Saudi Arabia (~55% of regional spend) and the UAE (~20%). Growth is concentrated in oncology, autoimmune, and diabetes biologics, with biosimilar penetration accelerating after SFDA and MOHAP pathways matured in 2024–2025.',
  },
  {
    question: 'How big is the GCC generic injectables market?',
    answer:
      'The GCC generic injectables market is approximately USD 1.6–1.9 billion in 2026, with Saudi Arabia and the UAE accounting for the majority of hospital-administered volume. Demand is shaped by NUPCO tendering in KSA, MOHAP listing in the UAE, and a growing focus on local manufacturing under Vision 2030.',
  },
  {
    question: 'What is the GCC drug repurposing market opportunity?',
    answer:
      'GCC drug repurposing is an emerging opportunity driven by oncology, rare disease, and metabolic indications. Saudi Arabia and the UAE both fund repurposing through R&D grants and public–private partnerships. BioNixus tracks repurposing pipelines, payer appetite, and physician adoption signals across the six GCC markets.',
  },
  {
    question: 'How is the Saudi Arabia precision medicine market evolving?',
    answer:
      'Saudi Arabia precision medicine is one of the fastest-growing GCC subsegments, with the Saudi Genome Program, Vision 2030 health pillar, and SFDA companion-diagnostic guidance driving adoption. Oncology, rare disease, and pharmacogenomics are the most active therapy areas, supported by King Faisal, King Abdulaziz Medical City, and major academic networks.',
  },
  {
    question: 'How does BioNixus support GCC pharmaceutical market research?',
    answer:
      'BioNixus runs primary physician and KOL research, quantitative tracker programs, market access and pricing studies, KOL mapping, and competitive intelligence across Saudi Arabia, the UAE, Kuwait, Qatar, Bahrain, and Oman. Programs are bilingual (Arabic/English), SFDA/MOHAP-aware, and aligned to launch, access, and growth decision windows.',
  },
  {
    question: 'Which GCC therapy areas drive the most pharma growth in 2026?',
    answer:
      'In 2026, the fastest-growing GCC therapy areas are oncology, diabetes and obesity (GLP-1 driven), rare disease, immunology, and cardiovascular. Saudi Arabia and the UAE concentrate the bulk of innovative-medicine spend, while Kuwait and Qatar prioritize tendered generic and hospital-administered portfolios.',
  },
];

const FAQ_SECTION_ID = 'gcc-pharma-research-faq';

const faqPageSchema = {
  '@context': 'https://schema.org',
  '@type': 'FAQPage',
  url: `${pageUrl}#${FAQ_SECTION_ID}`,
  mainEntity: FAQ_ITEMS.map((item) => ({
    '@type': 'Question',
    name: item.question,
    acceptedAnswer: { '@type': 'Answer', text: item.answer },
  })),
};

const breadcrumbSchema = {
  '@context': 'https://schema.org',
  '@type': 'BreadcrumbList',
  itemListElement: [
    { '@type': 'ListItem', position: 1, name: 'Home', item: 'https://www.bionixus.com/' },
    { '@type': 'ListItem', position: 2, name: 'GCC Pharmaceutical Market Research', item: pageUrl },
  ],
};

const articleSchema = {
  '@context': 'https://schema.org',
  '@type': 'Article',
  headline: 'GCC Pharmaceutical Market Research — Biologics, Generic Injectables & Precision Medicine 2026',
  description:
    'GCC pharmaceutical market research with biologics, generic injectables, drug repurposing, and Saudi Arabia precision medicine intelligence for launch, access, and growth decisions.',
  url: pageUrl,
  datePublished: '2025-09-01',
  dateModified: '2026-05-25',
  author: { '@type': 'Organization', '@id': 'https://www.bionixus.com/#organization', name: 'BioNixus' },
  publisher: { '@type': 'Organization', '@id': 'https://www.bionixus.com/#organization', name: 'BioNixus' },
};

export default function GccPharmaceuticalMarketResearch() {
  return (
    <div className="min-h-screen bg-background">
      <Helmet>
        {/* Title <= 60 chars (post-decode) so the suffix-truncate logic in
            api/indexnow-key.ts never clips the visible portion. */}
        <title>GCC Biologics, Injectables & Precision Medicine | BioNixus</title>
        <meta
          name="description"
          content="GCC pharmaceutical market research — biologics, generic injectables, drug repurposing, and Saudi Arabia precision medicine intelligence."
        />
        <link rel="canonical" href={pageUrl} />
        <meta property="og:title" content="GCC Pharmaceutical Market Research — Biologics, Injectables & Precision Medicine 2026" />
        <meta property="og:description" content="Decision-ready GCC pharma research: biologics, generic injectables, drug repurposing, and Saudi Arabia precision medicine intelligence." />
        <meta property="og:type" content="article" />
        <meta property="og:url" content={pageUrl} />
        <script type="application/ld+json">{JSON.stringify(articleSchema)}</script>
        <script type="application/ld+json">{JSON.stringify(breadcrumbSchema)}</script>
        <script type="application/ld+json">{JSON.stringify(faqPageSchema)}</script>
      </Helmet>
      <Navbar />
      <main>
        <BreadcrumbNav items={[{ name: 'Home', href: '/' }, { name: 'GCC Pharmaceutical Market Research', href: '/gcc-pharmaceutical-market-research' }]} />
        <section className="section-padding py-14">
          <div className="container-wide max-w-5xl mx-auto">
            <h1 className="text-3xl md:text-4xl font-display font-semibold text-foreground mb-4">
              GCC Pharmaceutical Market Research — Biologics, Generic Injectables &amp; Precision Medicine 2026
            </h1>
            <p className="text-muted-foreground leading-relaxed mb-5">
              GCC pharmaceutical market research for launch, access, and growth across Saudi Arabia, the UAE, Kuwait, Qatar, Bahrain, and Oman.
              This page covers the four sub‑segments where the regional market is moving fastest in 2026: the
              <strong> GCC biologics market</strong>, the <strong>GCC generic injectables market</strong>, <strong>GCC drug repurposing</strong>,
              and the <strong>Saudi Arabia precision medicine market</strong>. For the full research framework, return to the{' '}
              <Link to="/healthcare-market-research" className="text-primary font-semibold underline underline-offset-2 hover:no-underline">
                EMEA healthcare market research hub
              </Link>
              .
            </p>
            <div className="grid md:grid-cols-2 gap-4">
              <article className="rounded-xl border border-border bg-card p-5">
                <h2 className="font-semibold text-foreground mb-2">GCC biologics &amp; generic injectables market</h2>
                <p className="text-sm text-muted-foreground">Saudi Arabia and the UAE concentrate the majority of biologics and hospital injectables spend; tracker programmes follow biosimilar penetration, NUPCO tenders, and MOHAP listing.</p>
              </article>
              <article className="rounded-xl border border-border bg-card p-5">
                <h2 className="font-semibold text-foreground mb-2">Saudi Arabia precision medicine &amp; GCC drug repurposing</h2>
                <p className="text-sm text-muted-foreground">The Saudi Genome Program and SFDA companion-diagnostic guidance are unlocking precision-medicine launches; regional drug-repurposing activity is rising in oncology and rare disease.</p>
              </article>
            </div>

            <div className="mt-10 space-y-4 text-muted-foreground leading-relaxed max-w-4xl">
              <h2 className="text-xl font-display font-semibold text-foreground">How GCC pharmaceutical market research differs from a generic regional study</h2>
              <p>
                Gulf markets share Arabic language touchpoints and Gulf Cooperation Council coordination on several policy
                themes, but payer logic, hospital procurement, and retail pharmacy dynamics still diverge materially
                between Riyadh, Dubai, Doha, and Manama. Effective GCC pharmaceutical market research therefore sequences
                evidence by country, aligns instruments to bilingual respondent preferences, and respects authority-specific
                confidentiality norms for physicians and payers.
              </p>
              <p>
                BioNixus designs modules for launch sequencing, pricing and access narratives, patient support program
                adoption, and competitive switching in crowded therapeutic classes. Where Saudi Vision 2030 reforms accelerate
                localization expectations, research must connect SFDA registration pathways to hospital formulary behavior
                and retail activation. Where UAE free-zone models influence access, interviews must capture both DHA and
                MOHAP realities alongside private hospital networks.
              </p>
              <p>
                Quantitative programs typically combine representative physician samples with clear screening for
                prescribing volume and institution type. Qualitative work layers KOL, payer, and pharmacist perspectives to
                explain why quantitative signals move—or stall—after policy announcements. Reporting should translate those
                signals into account lists, messaging guardrails, and scenario planning for leadership committees rather than
                stopping at chart decks.
              </p>
            </div>

            <div className="mt-8 flex flex-wrap gap-3">
              <Link to="/bionixus-market-research-middle-east" className="rounded-lg bg-primary px-4 py-2.5 text-sm font-semibold text-primary-foreground">
                Open Middle East Pharmaceutical Market Research Pillar
              </Link>
              <Link to="/patient-support-program-research-gcc" className="rounded-lg border border-border px-4 py-2.5 text-sm font-semibold text-foreground hover:bg-muted">
                Patient support program research GCC
              </Link>
              <Link to="/contact" className="rounded-lg border border-border px-4 py-2.5 text-sm font-semibold text-foreground hover:bg-muted">
                Book a strategy call
              </Link>
            </div>
          </div>
        </section>

        <FAQSection
          sectionId={FAQ_SECTION_ID}
          title="GCC pharmaceutical market — biologics, injectables, precision medicine &amp; drug repurposing FAQ"
          items={FAQ_ITEMS}
          className="bg-muted/30"
        />
      </main>
      <Footer />
    </div>
  );
}

